Sun et al. (2017) reported that DUXAP8, upregulated in non-small cell lung cancer and an unfavorable prognostic biomarker, significantly facilitated cell growth, migration and invasion, and impaired apoptosis both in vitro and in vivo by epigenetically silencing EGR1 and RHOB. DUXAP10 expression was identified to be overexpressed in non-small cell lung cancer tissues and cell lines and its upregulation was correlated with poor prognosis of patients with non-small cell lung cancer (Wei C.C. et al., 2017). Here, DUXAP8 is linked to non-small cell lung carcinoma.